The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Joshua D Rosenblat, Ron Kakar, Roger S McIntyre, Joshua D Rosenblat, Ron Kakar, Roger S McIntyre

Abstract

Background: Cognitive dysfunction is often present in major depressive disorder (MDD). Several clinical trials have noted a pro-cognitive effect of antidepressants in MDD. The objective of the current systematic review and meta-analysis was to assess the pooled efficacy of antidepressants on various domains of cognition in MDD.

Methods: Trials published prior to April 15, 2015, were identified through searching the Cochrane Central Register of Controlled Trials, PubMed, Embase, PsychINFO, Clinicaltrials.gov, and relevant review articles. Data from randomized clinical trials assessing the cognitive effects of antidepressants were pooled to determine standard mean differences (SMD) using a random-effects model.

Results: Nine placebo-controlled randomized trials (2 550 participants) evaluating the cognitive effects of vortioxetine (n = 728), duloxetine (n = 714), paroxetine (n = 23), citalopram (n = 84), phenelzine (n = 28), nortryptiline (n = 32), and sertraline (n = 49) were identified. Antidepressants had a positive effect on psychomotor speed (SMD 0.16; 95% confidence interval [CI] 0.05-0.27; I(2) = 46%) and delayed recall (SMD 0.24; 95% CI 0.15-0.34; I(2) = 0%). The effect on cognitive control and executive function did not reach statistical significance. Of note, after removal of vortioxetine from the analysis, statistical significance was lost for psychomotor speed. Eight head-to-head randomized trials comparing the effects of selective serotonin reuptake inhibitors (SSRIs; n = 371), selective serotonin and norepinephrine reuptake inhibitors (SNRIs; n = 25), tricyclic antidepressants (TCAs; n = 138), and norepinephrine and dopamine reuptake inhibitors (NDRIs; n = 46) were identified. No statistically significant difference in cognitive effects was found when pooling results from head-to-head trials of SSRIs, SNRIs, TCAs, and NDRIs. Significant limitations were the heterogeneity of results, limited number of studies, and small sample sizes.

Conclusions: Available evidence suggests that antidepressants have a significant positive effect on psychomotor speed and delayed recall.

Keywords: antidepressants; cognitive function; executive function; major depressive disorder; psychomotor speed; working memory.

© The Author 2015. Published by Oxford University Press on behalf of CINP.

Figures

Figure 1.
Figure 1.
Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram of study selection.
Figure 2.
Figure 2.
Pooled effect for placebo-controlled trials assessing psychomotor speed. CI, confidence interval; DSST, Digit Symbol Sign Test; SD, standard definition.
Figure 3.
Figure 3.
Pooled effect of placebo-controlled trials assessing psychomotor speed sub-grouped based on age greater or less than 65 years. CI, confidence interval; DSST, Digit Symbol Sign Test; SD, standard definition.
Figure 4.
Figure 4.
Funnel-plot of placebo-controlled trials assessing psychomotor speed. SE, standard error; SMD, standard mean differences.
Figure 5.
Figure 5.
Pooled effect for placebo-controlled trials assessing cognitive control (Stroop test). CI, confidence interval; SD, standard definition.
Figure 6.
Figure 6.
Pooled effect for placebo-controlled trials assessing executive function (Trails Making Test-B). CI, confidence interval; SD, standard definition.
Figure 7.
Figure 7.
Pooled effect for placebo-controlled trials assessing delayed recall (Rey Auditory Verbal Learning Test). CI, confidence interval; SD, standard definition.
Figure 8.
Figure 8.
Pooled effect on memory for selective serotonin reuptake inhibitors (SSRI)/selective serotonin and norepinephrine reuptake inhibitors (SNRI) versus tricyclic antidepressants (TCA). CI, confidence interval; RBMT, Rivermead Behavioural Memory Test; SD, standard definition; STM, short term memory.
Figure 9.
Figure 9.
Pooled effect on working memory for selective serotonin reuptake inhibitors (SSRI) versus norepinephrine and dopamine reuptake inhibitors (NDRI). CI, confidence interval; SD, standard definition; SNRI, selective serotonin and norepinephrine reuptake inhibitors.
Figure 10.
Figure 10.
Pooled effect on psychomotor speed (Digit Symbol Sign Test [DSST]) for sertraline versus fluoxetine. CI, confidence interval; SD, standard definition.

References

    1. Baune BT, Miller R, McAfoose J, Johnson M, Quirk F, Mitchell D. (2010) The role of cognitive impairment in general functioning in major depression. Psychiatry Res 176:183–189.
    1. Baune BT, Renger L. (2014) Pharmacological and non-pharmacological interventions to improve cognitive dysfunction and functional ability in clinical depression--a systematic review. Psychiatry Res 219:25–50.
    1. Bondareff W, Alpert M, Friedhoff AJ, Richter EM, Clary CM, Batzar E. (2000) Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life. Am J Psych 157:729–736.
    1. Bora E, Harrison BJ, Yucel M, Pantelis C. (2013) Cognitive impairment in euthymic major depressive disorder: a meta-analysis. Psychol Med 43:2017–2026.
    1. Bortolato B, Carvalho AF, McIntyre RS. (2014) Cognitive dysfunction in major depressive disorder: a state-of-the-art clinical review. CNS Neurol Disord Drug Targets 13:1804–1818.
    1. Culang ME, Sneed JR, Keilp JG, Rutherford BR, Pelton GH, Devanand DP, Roose SP. (2009) Change in cognitive functioning following acute antidepressant treatment in late-life depression. Am J Geriat Psychiatry 17:881–888.
    1. Culang-Reinlieb ME, Sneed JR, Keilp JG, Roose SP. (2012) Change in cognitive functioning in depressed older adults following treatment with sertraline or nortriptyline. Int J Geriatr Psychiatry 27:777–784.
    1. Ferguson JM, Wesnes KA, Schwartz GE. (2003) Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. Int Clin Psychopharmacol 18:9–14.
    1. Finkel SI, Richter EM, Clary CM, Batzar E. (1999) Comparative efficacy of sertraline vs. fluoxetine in patients age 70 or over with major depression. Am J Geriat Psychiatry 7:221–227.
    1. Georgotas A, McCue RE, Reisberg B, Ferris SH, Nagachandran N, Chang I, Mir P. (1989) The effects of mood changes and antidepressants on the cognitive capacity of elderly depressed patients. Int Psychogeriatr 1:135–143.
    1. Gorlyn M, Keilp J, Burke A, Oquendo M, Mann JJ, Grunebaum M. (2015) Treatment-related improvement in neuropsychological functioning in suicidal depressed patients: paroxetine vs. bupropion. Psychiatry Res 225:407–412.
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. (2003) Measuring inconsistency in meta-analyses. The BMJ 327:557–560.
    1. Hoffman BM, Blumenthal JA, Babyak MA, Smith PJ, Rogers SD, Doraiswamy PM, Sherwood A. (2008) Exercise fails to improve neurocognition in depressed middle-aged and older adults. Med Sci Sports Exerc 40:1344–1352.
    1. Katona C, Hansen T, Olsen CK. (2012) A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 27:215–223.
    1. Keefe RS, McClintock SM, Roth RM, Doraiswamy PM, Tiger S, Madhoo M. (2014) Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review. J Clin Psychiatry 75:864–876.
    1. Kessler RC, Akiskal HS, Ames M, Birnbaum H, Greenberg P, Hirschfeld RM, Jin R, Merikangas KR, Simon GE, Wang PS. (2006) Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am J Psych 163:1561–1568.
    1. Lee RS, Hermens DF, Porter MA, Redoblado-Hodge MA. (2012) A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder. J Affect Disord 140:113–124.
    1. Levkovitz Y, Caftori R, Avital A, Richter-Levin G. (2002) The SSRIs drug Fluoxetine, but not the noradrenergic tricyclic drug Desipramine, improves memory performance during acute major depression. Brain Res Bull 58:345–350.
    1. Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS. (2015) A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. Neuropsychopharmacology 40:2025–2037.
    1. Marazziti D, Consoli G, Picchetti M, Carlini M, Faravelli L. (2010) Cognitive impairment in major depression. Eur J Pharmacol 626:83–86.
    1. McIntyre RS, Cha DS, Soczynska JK, Woldeyohannes HO, Gallaugher LA, Kudlow P, Alsuwaidan M, Baskaran A. (2013) Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety 30:515–527.
    1. McIntyre RS, Lophaven S, Olsen CK. (2014) A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychop 17:1557–1567.
    1. Newhouse PA, Krishnan KR, Doraiswamy PM, Richter EM, Batzar ED, Clary CM. (2000) A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. J Clin Psychiatry 61:559–568.
    1. Nickel T, Sonntag A, Schill J, Zobel AW, Ackl N, Brunnauer A, Murck H, Ising M, Yassouridis A, Steiger A, Zihl J, Holsboer F. (2003) Clinical and neurobiological effects of tianeptine and paroxetine in major depression. J Clin Psychopharmacol 23:155–168.
    1. Raskin J, Wiltse CG, Siegal A, Sheikh J, Xu J, Dinkel JJ, Rotz BT, Mohs RC. (2007) Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psych 164:900–909.
    1. Robinson M, Oakes TM, Raskin J, Liu P, Shoemaker S, Nelson JC. (2014) Acute and long-term treatment of late-life major depressive disorder: duloxetine versus placebo. Am J Geriatr Psychiatry 22:34–45.
    1. Soczynska JK, Ravindran LN, Styra R, McIntyre RS, Cyriac A, Manierka MS, Kennedy SH. (2014) The effect of bupropion XL and escitalopram on memory and functional outcomes in adults with major depressive disorder: results from a randomized controlled trial. Psychiatry Res 220:245–250.
    1. Strauss E SE, Spreen O. 2006. A compendium of neuropsychological tests: administration, norms, and commentary. NY: Oxford University Press.
    1. Trick L, Stanley N, Rigney U, Hindmarch I. (2004) A double-blind, randomized, 26-week study comparing the cognitive and psychomotor effects and efficacy of 75mg (37.5mg b.i.d.) venlafaxine and 75mg (25mg mane, 50mg nocte) dothiepin in elderly patients with moderate major depression being treated in general practice. J Psychopharmacol 18:205–214.
    1. World Health Organization (2012) Depression Fact Sheet. Geneva, Switzerland: World Health Organization.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi